Location of Repository

In silico regulatory analysis for exploring human disease progression

By Dustin T Holloway, Mark Kon and Charles DeLisi
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2464594
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1996). 3rd: Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene
    2. (1997). A clinical overview of WT1 gene mutations. Human Mutation
    3. (1996). A non-AUG translational initiation event generates novel WT1 isoforms.
    4. (2001). A novel method of protein secondary structure prediction with high segment overlap measure:support vector machine approach.
    5. (2004). A o z a s a K , M o n d e n M , S u g i y a m a H : Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Research
    6. (2006). A: FGFR3 mutations in benign skin tumors. Cell Cycle
    7. (2002). A: Inhibition of PDE3B Augments PDE4 Inhibitor-induced Apoptosis in a Subset of Patients with Chronic Lymphocytic Leukemia. Clin Cancer Res
    8. (1991). A: Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours. Anticancer Res
    9. (1999). A: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
    10. (1999). AG: Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties.
    11. (2004). AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell
    12. (1993). AJ: WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science
    13. (1998). Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters. Genes, Chromosomes and Cancer
    14. (1991). Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA
    15. (1998). Analysis of WT1 target gene expression in stably transfected cell lines. Oncogene
    16. (1995). Antagonism of WT1 activity by protein self-association.
    17. (1999). AS: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
    18. (2003). Aspects of tuberous sclerosis complex (TSC) protein function in the brain. Biochem Soc Trans
    19. (2005). Assessing computational tools for the discovery of transcription factor binding sites. Nature Biotechnology
    20. (2005). AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer
    21. (1995). Atweh G: The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene
    22. (1990). Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science
    23. (2005). Bonavida B: Expression of transcription factor Yin Yang 1 in prostate cancer.
    24. (1993). BR: Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis. Cell Growth Differ
    25. (1993). BR: Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor.
    26. (2000). BR: Identification of connective tissue growth factor as a target of WT1 transcriptional regulation.
    27. (1996). BR: Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation.
    28. (2006). Breast tumor copy number aberration phenotypes and genomic instability.
    29. (2004). Brivanlou AH: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor.
    30. (2004). Brivanlou AH: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nature Medicine
    31. (2005). Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters.
    32. (2008). Classifying transcription factor targets and discovering relevant biological features. Biology Direct
    33. (1994). Clericuzio CL: "Molecular genetic analysis of the WT1 gene in patients suspected to have the Denys-Drash syndrome". Med Pediatric Oncology
    34. (2004). Combining pattern discovery and discriminant analysis to predict gene coregulation. Bioinformatics
    35. (1996). Coordinate Positioning of MEF2 and Myogenin Binding Sites. Gene
    36. Crispino JD: Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
    37. (2006). CS: A Critical Role for Tetraspanin
    38. (1998). DA: E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene
    39. (1997). DA: Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res
    40. (1999). DA: The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell
    41. (1995). DA: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev
    42. (1995). DA: WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
    43. (2003). Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
    44. (2006). DC: How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res
    45. (1990). DE: An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell
    46. (1991). DE: WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature
    47. (1993). Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1. J Pediatr
    48. (1995). Deuel TF: Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene
    49. (2002). DF: CBFA2T3 (MTG16) Is a Putative Breast Tumor Suppressor Gene from the Breast Cancer Loss of Heterozygosity Region at 16q24.3. Cancer Res
    50. (1993). Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet
    51. (2000). DNA Binding Sites: Representation and Discovery. Bioinformatics
    52. (1999). DR: Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1. Exp Cell Res
    53. (1994). E: Beckwith-Wiedemann syndrome.
    54. (2003). E: Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem Soc Trans
    55. (2003). Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells.
    56. (1997). Efstratiadis A: Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev
    57. (1999). Egeler RM: Genetics of Wilms' tumor. Seminars in Urologic Oncology
    58. (1986). Ehrenfeucht A: Information content of binding sites on nucleotide sequences.
    59. (2007). Eizirik D: In silico identification of NFkappaB-regulated genes in pancreatic beta-cells.
    60. (1993). Ekstrom TJ: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet
    61. (1994). EN: Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development
    62. (2006). Ensembl 2006. Nucleic Acids Res
    63. (2006). EPD in its twentieth year: towards complete promoter coverage of selected model organisms. Nucleic Acids Res
    64. (2003). Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep
    65. (2006). Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations.
    66. (1998). Extracting Regulatory Sites from the Upstream Region of Yeast Genes by Computational Analysis of Oligonucleotide Frequencies.
    67. Fast kernels for inexact string matching.
    68. (1996). Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA
    69. (1994). Fine structure analysis of the WT1 gene in sporadic Wilms tumors.
    70. (1993). FJ 3rd: Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus.
    71. (2005). Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis
    72. (1990). GA: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature
    73. (2002). Gene Selection for Cancer Classification using Support Vector Machines. Machine Learning
    74. (2005). Genome-wide promoter extraction and analysis in human, mouse, and rat. Genome Biology
    75. (1992). Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development. Nat Genet
    76. (2004). Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. Human Mutation
    77. (1996). GF: Differential Function of Wilms' Tumor Gene WT1 Splice Isoforms in Transcriptional Regulation.
    78. (1999). GF: Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1. Anticancer Res
    79. (1997). GF: The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerian-inhibiting substance, and the androgen receptor. Clin Cancer Res
    80. (2004). Gingeras TR: Unbiased Mapping of Transcription Factor Binding Sites along Human Chromosomes 21 and 22 Points to Widespread Regulation of Noncoding RNAs. Cell
    81. (2004). Haussler D: Combining Phylogenetic and Hidden Markov Models in Biosequence Analysis.
    82. (2005). Haussler D: Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res
    83. (2000). Haussler D: Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics
    84. (2002). Henske EP: Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene
    85. (2006). High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res
    86. (2004). Hoffman EP: Embryonic myogenesis pathways in muscle regeneration. Dev Dyn
    87. (2001). Hua : Support vector machine approach for protein subcellular localization prediction. Bioinformatics
    88. (2005). Huff V: Genome-wide loss of heterozygosity analysis of WT1-wildtype and WT1-mutant Wilms tumors. Genes Chromosomes Cancer
    89. (2002). Identification and expression analysis of the human mu-protocadherin gene in fetal and adult kidneys.
    90. (2003). Increased Activation of CCAAT/Enhancer Binding Protein-{beta} Correlates with the Invasiveness of Renal Cell Carcinoma. Clin Cancer Res
    91. (1998). Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev
    92. (2004). Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncology Reports
    93. (2005). Integrating genomic data to predict transcription factor binding. Genome Informatics
    94. (2006). Introduction to Data Mining.
    95. (2005). Ioannou P: Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.
    96. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell
    97. (1994). JA: Towards a genetic basis for kidney development. Mechanisms of Development
    98. (1993). JB: The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mechanisms of Development
    99. (2005). K-C: Using string kernel to predict signal peptide cleavage site based on subsite coupling model. Amino Acids
    100. (2000). K-R: Engineering support vector machine kernels that recognize translation initiation sites. Bioinformatics
    101. (2006). Kel AE, Wingender E: TRANSFAC(R) and its module TRANSCompel(R): transcriptional gene regulation in eukaryotes. Nucleic Acids Res
    102. (1994). Kim SJ: Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol
    103. (1999). Krolewski AS: Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus.
    104. (1994). KW: Autoregulation of the human WT1 gene promoter.
    105. (2004). L: OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res
    106. (2001). L: The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor.
    107. (1995). LeRoith D: Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol
    108. (2000). Licht JD: Ecadherin is a WT1 target gene.
    109. (1995). Licht JD: WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins.
    110. Lin C-J: LIBSVM: a Library for Support Vector Machines.
    111. (1997). LM: The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas.
    112. (1994). Loss of heterozygosity for chromosomes 16q and p1 in Wilms' tumors predicts an adverse outcome. Cancer Research
    113. (2006). Machine Learning for Predicting Targets of Transcription Factors
    114. (2007). Machine Learning for Regulatory Analysis and Transcription Factor Target Prediction in Yeast. Systems and Synthetic Biology
    115. (2006). Machine Learning Methods for Transcription Data Integration.
    116. (2001). Malik KT: The molecular biology of Wilms' tumor. Expert Reviews in Molecular Medicine
    117. (2005). Mapping DNA-protein interactions in large genomes by sequence tag analysis of genomic enrichment. Nature Methods
    118. (2006). Mechanisms controlling embryonic stem cell self-renewal and differentiation. Crit Rev Eukaryot Gene Expr
    119. (1999). MM: The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ
    120. (1999). Morisaki T: Expression of MEF2 genes during human cardiac development. Tohoku J Exp Med
    121. (2004). MS: Antagonism between DNA hypermethylation and enhancer-blocking activity at the H19 DMD is uncovered by CpG mutations. Nat Genet
    122. (2004). MS: Role of H19 3' sequences in controlling H19 and Igf2 imprinting and expression. Genomics
    123. (1994). Nasu K: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood
    124. (1992). ND: Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA
    125. (2003). Oosterhuis JW: POU5F1 (OCT3/4) Identifies Cells with Pluripotent Potential in Human Germ Cell Tumors. Cancer Res
    126. (2006). Orkin SH: A protein interaction network for pluripotency of embryonic stem cells. Nature
    127. (1998). orphan nuclear receptor SF-1 in sex-specific gene expression. Cell
    128. (2003). Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Science
    129. (2004). Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Science
    130. (2004). Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Science
    131. Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer.
    132. (2006). Patsouris E: FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. Anticancer Res
    133. (1988). Pearson P: Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours. Human Genetics
    134. (1996). Perbal B: Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene
    135. (2001). Pesole G: An algorithm for finding signals of unknown length in DNA sequences. Bioinformatics
    136. (2006). Pesole G: MoD Tools: regulatory motif discovery in nucleotide sequences from co-regulated or homologous genes. Nucleic Acids Res
    137. (2004). Pesole G: Weeder Web: discovery of transcription factor binding sites in a set of sequences from co-regulated genes. Nucleic Acids Res
    138. (2000). Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1. Biochem Biophys Res Commun
    139. (2001). Polonsky KS: Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young.
    140. (1993). Polychronakos C: Parental genomic imprinting of the human IGF2 gene. Nat Genet
    141. (1999). Probabilistic Outputs for Support Vector Machines and Comparisons to Regularized Likelihood Methods.
    142. (2004). RA: Control of Pancreas and Liver Gene Expression by HNF Transcription Factors. Science
    143. (2005). RA: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell
    144. (2005). Radvanyi F: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet
    145. (2005). Rajpert-De Meyts E: Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology
    146. (1995). Rauscher FJ 3rd, Ercolani L: LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i2 protooncogene transcription.
    147. (2008). Rauscher FJ 3rd: Repression of the insulin-like growth factor IIBiology Direct
    148. (1992). Rauscher FJ 3rd: The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene.
    149. (1991). Rauscher FJ III: Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science
    150. (2006). Real FX: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
    151. (2008). Reeve AE: Constitutional relaxation of insulin-like growth fac-Biology Direct
    152. (2003). Regulatory sequence analysis tools.
    153. (1995). Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene
    154. (2004). RH: Defining the CREB Regulon: A Genome-Wide Analysis of Transcription Factor Regulatory Regions. Cell
    155. (1997). RJ: Organization and Myogenic Restricted Expression of the Murine Serum Response Factor Gene. A Role for Autoregulation.
    156. (1993). Roberts CT Jr: Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA
    157. (1990). Role for the Wilms Tumor Gene in Genital Development. Proc Natl Acad Sci USA
    158. (2002). Romashchenko AG: Transcription Regulatory Regions Database (TRDD): its status in 2002. Nucleic Acids Res
    159. (1995). Roosen CB: An introduction to multivariate adaptive regression splines. Stat Methods Med Res
    160. (1993). S e n s D , G a r v i n A : WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science
    161. (2006). S: Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA
    162. (2006). Saglio G: WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Methods in Molecular Medicine
    163. (2006). Saqi MA: Predicting deleterious nsSNPs: an analysis of sequence and structural attributes.
    164. (1994). Saunders G: Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter.
    165. (1995). Saunders GF: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res
    166. (1995). Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol
    167. (1990). Sequence logos: a new way to display consensus sequences. Nucleic Acids Res
    168. (2007). Serum response factor binding sites differ in three human cell types. Genome Res
    169. Sinz F: SPIDER, object oriented machine learning library.
    170. (2006). SJM: ORegAnno: an open access database and curation system for literaturederived promoters, transcription factor binding sites and regulatory variation. Bioinformatics
    171. (2004). Smith A: Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene
    172. (2006). Soejima H: Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
    173. (2003). Soejima H: Significant Reduction of WT1 Gene Expression, Possibly Due to Epigenetic Alteration in Wilms' Tumor.
    174. (1998). Statistical Learning Theory.
    175. Stormo GD: ANN-Spec: a method for discovering transcription factor binding sites with improved specificity.
    176. (1972). Strong LC: Mutation and cancer: a model for Wilms' tumor of the kidney.
    177. (1991). Structural rearrangements of the WT1 gene in Wilms' tumour cells. Oncogene
    178. (2002). Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.
    179. (2003). Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Science
    180. (2003). Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Science
    181. (1992). Sukhatme VP: Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA
    182. (1994). Sukhatme VP: The Wilms' tumor suppressor gene WT1 is negatively autoregulated.
    183. (1994). Sukumar S: RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev
    184. (2001). Sukumar S: Wilms' Tumor Suppressor Gene (WT1) Is Expressed in Primary Breast Tumors Despite Tumor-specific Promoter Methylation. Cancer Res
    185. (2004). Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    186. (2003). Swinnen JV: RNA Interference-mediated Silencing of the Fatty Acid Synthase Gene Attenuates Growth and Induces Morphological Changes and Apoptosis of LNCaP Prostate Cancer Cells. Cancer Res
    187. (2006). T: Differential effects of GATA-1 on proliferation and differentiation of erythroid lineage cells. Blood
    188. (1996). T: Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet
    189. (1997). T: Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of
    190. (1996). T: Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). Oncogene
    191. (1993). TF: The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains.
    192. (1994). The Denys-Drash syndrome.
    193. (2006). The Mathworks.
    194. (2004). The molecular basis of pluripotency in mouse embryonic stem cells. Cloning And Stem Cells
    195. (1999). The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol
    196. (2007). Thomson JA: Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res
    197. (1991). Tilghman SM: Parental imprinting of the mouse H19 gene. Nature
    198. (1995). Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci USA
    199. (2003). TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem Soc Trans
    200. (1999). Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control.
    201. (2003). Tycko B: Biallelic expression of HRAS and MUCDHL in human and mouse. Hum Genet
    202. (2005). Tycko B: Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res
    203. (1999). Using the Fisher kernel method to detect remote protein homologies.
    204. (2004). VisANT: an online visualization and analysis tool for biological interaction data.
    205. (2005). VisANT: data-integrating visual framework for biological networks and modules. Nucleic Acids Res
    206. (2005). Wang WL: Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells.
    207. (2006). Weng Z: A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome. Cell
    208. (2001). Wilms tumor and the WT1 gene. Exp Cell Res
    209. (2001). Wilms Tumor and the WT1 Gene. Experimental Cell Research
    210. (2003). WJ: The UCSC Genome Browser Database. Nucl Acids Res
    211. (2004). WJ: The UCSC Table Browser data retrieval tool. Nucleic Acids Res
    212. (2005). WS: Kernels for Gene Regulatory Regions.
    213. (2004). WS: Mismatch string kernels for discriminative protein classification. Bioinformatics
    214. (2002). WS: The Spectrum Kernel: A string kernel for SVM protein classification. Pac Symp Biocomput
    215. (1996). Yeung RS: Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci USA
    216. (2006). Zhang MQ: Adaptively inferring human transcriptional subnetworks. Molecular Systems Biology
    217. (2004). Zhao B: Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor. Cancer Gene Ther
    218. (2005). Zwarthoff EC: A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine. Clin Cancer Res
    219. (2001). ZY: Rb-associated protein 46 (RbAp46) suppresses the tumorigenicity of adenovirus-transformed human embryonic kidney 293 cells.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.